Exelixis (EXEL) Convertible Debt (2010 - 2017)
Exelixis' (EXEL) quarterly Convertible Debt came in at $113.3 million in Q1 2017, down 59.68% year-on-year from $281.2 million in Q1 2016, and up 39.09% quarter-over-quarter from $81.5 million in Q3 2016.
Exelixis (EXEL) Convertible Debt (2010 - 2017) Analysis & Trends
Exelixis' Convertible Debt history runs 8 years deep, the most recent figure standing at $113.3 million for Q1 2017.
- On a quarterly basis, Convertible Debt fell 59.68% year-over-year to $113.3 million in Q1 2017; TTM through Mar 2017 was $113.3 million, a 59.68% decrease from a year earlier, with the FY2015 full-year figure at $337.9 million, up 51.12% from the prior year.
- Convertible Debt rose to $113.3 million in Q1 2017 per EXEL's latest filing, from $81.5 million in the prior quarter.
- Across five years, Convertible Debt topped out at $337.9 million in Q4 2015 and bottomed at $81.5 million in Q3 2016.
- The 5-year median for Convertible Debt is $255.1 million (2013), against an average of $240.1 million.
- Across the five-year window, Convertible Debt soared 182.83% in 2013 and slumped 72.6% in 2016, its largest moves.
- Year by year, Convertible Debt stood at $301.6 million in 2013, then dropped by 25.84% to $223.6 million in 2014, then soared by 51.12% to $337.9 million in 2015, then slumped by 75.89% to $81.5 million in 2016, then soared by 39.09% to $113.3 million in 2017.
- Per Business Quant, the three latest EXEL Convertible Debt figures stand at $113.3 million (Q1 2017), $81.5 million (Q3 2016), and $288.6 million (Q2 2016).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 113.35 Mn |
| Sep 30, 2016 | 81.49 Mn |
| Jun 30, 2016 | 288.56 Mn |
| Mar 31, 2016 | 281.16 Mn |
| Dec 31, 2015 | 337.94 Mn |
| Sep 30, 2015 | 297.44 Mn |
| Jun 30, 2015 | 291.23 Mn |
| Mar 31, 2015 | 284.36 Mn |
| Dec 31, 2014 | 223.63 Mn |
| Sep 30, 2014 | 177.96 Mn |
| Jun 30, 2014 | 173.64 Mn |
| Mar 31, 2014 | 261.41 Mn |
| Dec 31, 2013 | 301.55 Mn |
| Sep 30, 2013 | 248.71 Mn |
| Jun 30, 2013 | 242.46 Mn |
| Mar 31, 2013 | 236.39 Mn |
| Dec 31, 2012 | 291.83 Mn |
| Sep 30, 2012 | 239.24 Mn |
| Jun 30, 2012 | 85.86 Mn |
| Mar 31, 2012 | 83.58 Mn |